Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMN for Immune Cell Rejuvenation in Adults
NCT05984550Phase 1Unknown
- Sponsor
- Shanghai Cell Therapy Group
- Start
- Aug 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nicotinamide mononucleotide in aging, sponsored by Shanghai Cell Therapy Group. Primary endpoints: Changes in Nicotinamide mononucleotide (Vital NAD) in whole blood at 30 days, Changes in NAD+ and NADH concentrations in whole blood at 30 days and 5 more. Status: unknown.
02
Drugs
nicotinamide mononucleotide
03
Conditions
aging
Beyond the preview
Go deeper on NCT05984550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984550.